Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

Martijn W.C. Verbeek; Chiara Buracchi; Anna Laqua; Stefan Nierkens; Lukasz Sedek; Juan Flores-Montero; Mattias Hofmans; Elaine Sobral de Costa; Michaela Nováková; Ester Mejstrikova; Susana Barrena; Saskia Kohlscheen; Monika Szczepanowski; Jan Kulis; Elen Oliveira; Romana Jugooa; Anja X. de Jong; Tomasz Szczepanski; Jan Philippé; Jacques J.M. van Dongen; Alberto Orfao; Monika Brüggemann; Giuseppe Gaipa; Vincent H.J. van der Velden

doi:10.1111/bjh.17992

Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

Martijn W.C. Verbeek
, Chiara Buracchi
, Anna Laqua
, Stefan Nierkens
, Lukasz Sedek
, Juan Flores-Montero
, Mattias Hofmans
, Elaine Sobral de Costa
, Michaela Nováková
, Ester Mejstrikova
, Susana Barrena
, Saskia Kohlscheen
, Monika Szczepanowski
, Jan Kulis
, Elen Oliveira
, Romana Jugooa
, Anja X. de Jong
, Tomasz Szczepanski
, Jan Philippé
, Jacques J.M. van Dongen

Alberto Orfao, Monika Brüggemann, Giuseppe Gaipa, Vincent H.J. van der Velden

Group Nierkens

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.

Original language	English
Pages (from-to)	76-81
Number of pages	6
Journal	British journal of haematology
Volume	197
Issue number	1
DOIs	https://doi.org/10.1111/bjh.17992
Publication status	Published - Apr 2022

Keywords

acute leukaemia
diagnostic haematology
flow cytometry
minimal residual disease
Neoplasm, Residual
Adaptor Proteins, Signal Transducing
Antigens, CD19/therapeutic use
Humans
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
Flow Cytometry/methods
Burkitt Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Access to Document

10.1111/bjh.17992

Cite this

Verbeek, M. W. C., Buracchi, C., Laqua, A., Nierkens, S., Sedek, L., Flores-Montero, J., Hofmans, M., Sobral de Costa, E., Nováková, M., Mejstrikova, E., Barrena, S., Kohlscheen, S., Szczepanowski, M., Kulis, J., Oliveira, E., Jugooa, R., de Jong, A. X., Szczepanski, T., Philippé, J., ... van der Velden, V. H. J. (2022). Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study. British journal of haematology, 197(1), 76-81. https://doi.org/10.1111/bjh.17992

@article{0df5cb995c7342e0a46654ef761bc82b,

title = "Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study",

abstract = "The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92\% of targeted therapy patients who remained CD19-positive, whereas this was 81\% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.",

keywords = "acute leukaemia, diagnostic haematology, flow cytometry, minimal residual disease, Neoplasm, Residual, Adaptor Proteins, Signal Transducing, Antigens, CD19/therapeutic use, Humans, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis, Flow Cytometry/methods, Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma",

author = "Verbeek, \{Martijn W.C.\} and Chiara Buracchi and Anna Laqua and Stefan Nierkens and Lukasz Sedek and Juan Flores-Montero and Mattias Hofmans and \{Sobral de Costa\}, Elaine and Michaela Nov{\'a}kov{\'a} and Ester Mejstrikova and Susana Barrena and Saskia Kohlscheen and Monika Szczepanowski and Jan Kulis and Elen Oliveira and Romana Jugooa and \{de Jong\}, \{Anja X.\} and Tomasz Szczepanski and Jan Philipp{\'e} and \{van Dongen\}, \{Jacques J.M.\} and Alberto Orfao and Monika Br{\"u}ggemann and Giuseppe Gaipa and \{van der Velden\}, \{Vincent H.J.\}",

note = "{\textcopyright} 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley \& Sons Ltd.",

year = "2022",

month = apr,

doi = "10.1111/bjh.17992",

language = "English",

volume = "197",

pages = "76--81",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

Verbeek, MWC, Buracchi, C, Laqua, A, Nierkens, S, Sedek, L, Flores-Montero, J, Hofmans, M, Sobral de Costa, E, Nováková, M, Mejstrikova, E, Barrena, S, Kohlscheen, S, Szczepanowski, M, Kulis, J, Oliveira, E, Jugooa, R, de Jong, AX, Szczepanski, T, Philippé, J, van Dongen, JJM, Orfao, A, Brüggemann, M, Gaipa, G & van der Velden, VHJ 2022, 'Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study', British journal of haematology, vol. 197, no. 1, pp. 76-81. https://doi.org/10.1111/bjh.17992

Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study. / Verbeek, Martijn W.C.; Buracchi, Chiara; Laqua, Anna et al.
In: British journal of haematology, Vol. 197, No. 1, 04.2022, p. 76-81.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

AU - Verbeek, Martijn W.C.

AU - Buracchi, Chiara

AU - Laqua, Anna

AU - Nierkens, Stefan

AU - Sedek, Lukasz

AU - Flores-Montero, Juan

AU - Hofmans, Mattias

AU - Sobral de Costa, Elaine

AU - Nováková, Michaela

AU - Mejstrikova, Ester

AU - Barrena, Susana

AU - Kohlscheen, Saskia

AU - Szczepanowski, Monika

AU - Kulis, Jan

AU - Oliveira, Elen

AU - Jugooa, Romana

AU - de Jong, Anja X.

AU - Szczepanski, Tomasz

AU - Philippé, Jan

AU - van Dongen, Jacques J.M.

AU - Orfao, Alberto

AU - Brüggemann, Monika

AU - Gaipa, Giuseppe

AU - van der Velden, Vincent H.J.

PY - 2022/4

Y1 - 2022/4

N2 - The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.

AB - The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.

KW - acute leukaemia

KW - diagnostic haematology

KW - flow cytometry

KW - minimal residual disease

KW - Neoplasm, Residual

KW - Adaptor Proteins, Signal Transducing

KW - Antigens, CD19/therapeutic use

KW - Humans

KW - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis

KW - Flow Cytometry/methods

KW - Burkitt Lymphoma

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

UR - https://www.scopus.com/pages/publications/85120974952

U2 - 10.1111/bjh.17992

DO - 10.1111/bjh.17992

M3 - Article

C2 - 34881427

AN - SCOPUS:85120974952

SN - 0007-1048

VL - 197

SP - 76

EP - 81

JO - British journal of haematology

JF - British journal of haematology

IS - 1

ER -

Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

Abstract

Keywords

Access to Document

Fingerprint

Cite this